Daily Respiratory Research Analysis
Analyzed 343 papers and selected 3 impactful papers.
Summary
Key advances span mechanistic, diagnostic, and preventive respiratory research. A PNAS study identifies a gut-derived metabolite, oxindole, that suppresses CXCL13 to curb acute lung injury, linking tryptophan metabolism and the gut–lung axis. Clinically, a phase 3b trial supports extending an adjuvanted RSV prefusion F vaccine to at-risk adults aged 18–49 via immunobridging, and a population study shows race-neutral GLI-2022 equations materially shift spirometry interpretation with policy implications.
Research Themes
- Gut–lung axis and metabolic immunomodulation in acute lung injury
- Immunobridging to expand RSV vaccine indications in high-risk adults
- Race-neutral spirometry reference equations and clinical reclassification
Selected Articles
1. Microbial metabolite oxindole curbs acute lung injury by suppressing CXCL13.
This mechanistic study links dysregulated tryptophan metabolism in ARDS to the gut–lung axis and identifies oxindole as a protective microbial metabolite that suppresses CXCL13 to limit ALI. Dietary tryptophan modulated injury severity in a microbiota-dependent manner, establishing metabolic–immune crosstalk as a therapeutic target.
Impact: It provides a novel, microbiome-dependent mechanism for ALI/ARDS modulation and nominates oxindole–CXCL13 signaling as a tractable pathway. This mechanistic advance opens avenues for diet, microbiota, or metabolite-based interventions.
Clinical Implications: Although preclinical, the work suggests testable strategies: modulating tryptophan intake, restoring key gut taxa, or delivering oxindole analogs to dampen CXCL13-driven lung inflammation. It also supports biomarker development around tryptophan pathways in ARDS.
Key Findings
- Untargeted plasma metabolomics showed dysregulated tryptophan metabolism in ARDS versus healthy controls.
- High dietary tryptophan alleviated ALI severity while deficiency worsened it; protection required an intact gut microbiota.
- A microbial metabolite, oxindole, suppressed CXCL13 signaling and curtailed lung injury in murine models.
Methodological Strengths
- Integrated multi-omics and dietary intervention with microbiota dependence testing (16S rRNA sequencing).
- Mechanistic linkage from metabolite (oxindole) to chemokine (CXCL13) with in vivo functional validation.
Limitations
- Human data are observational metabolomics; causal inference in patients remains unproven.
- Translational safety, dosing, and pharmacology of oxindole in humans are unknown.
Future Directions: Validate oxindole–CXCL13 axis in human ALI/ARDS cohorts; test microbiome or metabolite-based interventions; define dose–response and safety of oxindole analogs; develop tryptophan-pathway biomarkers for risk stratification.
The gut-lung axis is involved in acute lung injury (ALI) and its fatal sequela, acute respiratory distress syndrome (ARDS), yet the molecular mechanisms governing this crosstalk remain poorly defined. Untargeted metabolomics of plasma revealed significant dysregulation of tryptophan metabolism in ARDS patients compared to healthy controls. Murine dietary interventions demonstrated that high tryptophan intake alleviated ALI severity, whereas deficiency exacerbated injury, with protection being gut microbiota dependent. 16S ribosomal RNA (16S rRNA) gene sequencing revealed marked depletion of a functionally central bacterium
2. Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18-49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years.
In a multicountry phase 3b immunobridging trial (n=1458), the AS01E-adjuvanted RSVPreF3 vaccine in at-risk adults aged 18–49 achieved immunological noninferiority to ≥60-year-olds, with robust RSV-A/B neutralization and CD4+ T-cell responses persisting above baseline at 6 months. Safety was acceptable, with more frequent but mostly mild–moderate solicited events in younger adults.
Impact: Findings support extending RSV vaccination to a high-risk younger adult population via immunobridging, potentially reducing RSV morbidity across a broader age range.
Clinical Implications: Guideline committees and payers may consider at-risk adults aged 18–49 for RSV vaccination based on immunobridging. Clinicians should anticipate higher reactogenicity in younger adults but largely mild–moderate and transient.
Key Findings
- Immunological noninferiority in RSV-A/B geometric mean titers and seroresponse at 1 month in at-risk 18–49-year-olds versus ≥60-year-olds.
- Neutralizing titers and RSVPreF3-specific CD4+ T-cell responses remained above baseline at 6 months in both groups.
- Solicited adverse events were more frequent in 18–49-year-olds (84.3% vs 69.4%) but were predominantly mild-to-moderate and transient; serious AEs were uncommon.
Methodological Strengths
- Large, multicountry phase 3b immunobridging design with prespecified noninferiority margins.
- Assessment of both humoral and cell-mediated immunity with 6-month durability.
Limitations
- Open-label design may introduce reporting bias in solicited events.
- Clinical efficacy endpoints (e.g., RSV LRTI) were not assessed; inference relies on immunobridging.
Future Directions: Prospective effectiveness studies in at-risk 18–49-year-olds, evaluation of coadministration strategies, longer-term durability, and surveillance for rare AEs.
BACKGROUND: The AS01E-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (adjuvanted RSVPreF3) is approved for ≥60-year-olds and 50-59-year-olds at increased risk of RSV disease. We evaluated the vaccine's immunogenicity and safety in 18-49-year-olds at increased risk of RSV disease due to certain chronic conditions. METHODS: This open-label, multicountry phase 3b trial included 18-49-year-olds at increased risk (at-risk 18-49 group) and a control group of ≥60-year-olds with or without chronic conditions (≥60 group). Primary objective was to demonstrate immunological noninferiority to adjuvanted RSVPreF3 in the at-risk 18-49 versus ≥60 group, based on group RSV-A/RSV-B geometric mean titer ratios and seroresponse rate differences 1 month postvaccination. Humoral, cell-mediated immunogenicity, and safety were assessed until 6 months postvaccination. RESULTS: Overall, 1458 adults were vaccinated. Immunological noninferiority was demonstrated in the at-risk 18-49 versus ≥60 group at 1 month postvaccination. Both groups showed increased RSV-A/RSV-B neutralizing titers and RSVPreF3-specific CD4+ T-cell frequencies at 1 month postvaccination that declined but remained above baseline at 6 months. Solicited events were more frequent in the at-risk 18-49 (84.3%) than in the ≥60 group (69.4%); most were mild-to-moderate and transient. Rates and intensity of unsolicited adverse events (AEs) were comparable across groups, with low reporting of serious AEs and AEs of special interest. CONCLUSIONS: Adjuvanted RSVPreF3 was immunologically noninferior in 18-49-year-olds with underlying conditions compared with ≥60-year-olds in whom efficacy was previously demonstrated, supporting efficacy inference in this younger population. Up to 6 months postvaccination, the vaccine elicited robust immune responses, and the safety profile was acceptable. Clinical Trial Registration: NCT06389487.
3. Impact of transitioning from Race-specific to Race-neutral GLI equation on lung function in a predominantly Caucasian population.
In a predominantly Caucasian cohort (n=3330 baseline; n=2005 FU), adopting race-neutral GLI-2022 increased %predicted and z-scores for FEV1 and FVC, with the largest shifts in younger males and those with lower education. Low FEV1/FVC prevalence decreased, while obstructive impairment prevalence increased, indicating substantial reclassification with clinical and policy relevance.
Impact: Demonstrates how race-neutral reference equations materially change impairment prevalence and spirometric interpretation, informing equitable diagnostics and potential updates to thresholds and reporting.
Clinical Implications: Clinicians should anticipate upward shifts in %predicted and z-scores and recalibrate impairment thresholds. Health systems may need to reassess eligibility for benefits or interventions tied to spirometric cutoffs under GLI-2022.
Key Findings
- GLI-2022 increased FEV1 %predicted by ~4.2–4.6% and FVC %predicted by ~4.9–5.6%, with z-score gains at both baseline and follow-up (p<0.0001).
- Greatest increases were seen in younger individuals, males, and those with only compulsory education.
- Prevalence of low FEV1 and low FVC decreased, whereas obstructive ventilatory impairment prevalence increased (all p<0.05).
Methodological Strengths
- Prospective population-based cohort with spirometry at baseline and follow-up.
- Stratified and regression analyses with multiple comparisons correction.
Limitations
- Predominantly Caucasian sample (>97%) limits generalizability to other ancestries.
- Clinical outcome impacts (e.g., misclassification costs) were not directly assessed.
Future Directions: Evaluate GLI-2022 impacts across diverse ancestries, link reclassification to outcomes and access, and harmonize reporting/thresholds for equitable respiratory care.
Introduction Diagnosis and treatment decisions for many respiratory diseases are based on spirometric values. We compared the impact of changing the reference equations from GLI-2012 (race-specific) to GLI-2022 (race-neutral) in a predominantly Caucasian urban population. Methods PneumoLaus is a sub-study of CoLaus|PsyCoLaus, an ongoing prospective observational study conducted in Lausanne, Switzerland. Participants performed spirometry at baseline (2014-2017) and at follow-up (2018-2021, FU). We analysed changes of %predicted values (PV) for Forced Expiratory Volume in One second (FEV1) and Forced Vital Capacity (FVC) by comparing the GLI-2022 reference equation to GLI-2012. Sub-group analyses were performed for social class, sex and age using paired t-tests corrected by Holm-Bonferroni. We analysed the association of age, sex and social class on the differences using linear regression. Results A total of 3330 participants were included at baseline and 2005 at FU, >97% Caucasian. Employing GLI-2022 equations, the %PV increased significantly for both FEV1 (4.2%PV and +0.31 Z-score baseline, 4.6%PV and +0.28 Z-score FU, both p<0.0001) and FVC (4.9%PV and +0.34 Z-score baseline, 5.6%PV and + 0.29 Z-score FU, both p<0.0001). Younger individuals, males, and participants with only compulsory school education experienced the greatest increase. The prevalence of low FEV₁ and low FVC decreased using GLI-2022 references, while the prevalence of obstructive ventilatory impairment increased at baseline and FU (all p<0.05). Discussion In this predominantly Caucasian urban population-based cohort, applying GLI-2022 equations led to a general FEV1 and FVC %PV increase, particularly among younger individuals, males, and participants with only compulsory school education. Applying GLI-2022 equations also led to a general FEV1 and FVC z-score increase. These findings changes may carry relevant implications for clinical care and social policy decisions.